Bcl-2 Inhibitor LOXO-338 clinical trials
Its developmentBy Fosun Pharma and Eli Lilly, step by step3 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses Bcl-2 Inhibitor LOXO-338 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Fochon Pharmaceuticals, Ltd. (1) · Eli Lilly and Company (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Bcl-2 Inhibitor LOXO-338.
- Dec 2026FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid NeoplasmsPhase 2 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Studies
Open first, then newest update. How each study uses Bcl-2 Inhibitor LOXO-338 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedPhase 1Eli Lilly and CompanyNCT05024045Written as LOXO-338
- FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid NeoplasmsActive, not recruitingPhase 2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT06858618Written as FCN-338 + Azacitidine
- A Study of FCN-338 in Patients With Chronic CLL/SLLActive, not recruitingPhase 1Fochon Pharmaceuticals, Ltd.NCT04682808Written as FCN-338